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Background: A growing number of patients who are on systemic anticoagulation with warfarin require endovenous
thermal ablation for reflux disease in the great saphenous vein (GSV). Little is known about the effects of anticoagulation
on periprocedural bleeding and long-term closure rates of the treated veins. This study evaluated the effects of
uninterrupted anticoagulation in patients undergoing endovenous thermal ablation.
Methods: In this prospective observational study, 88 limbs of patients on warfarin (anticoagulation group [AG]) who
underwent endovenous thermal ablation for GSV reflux disease were compared with 92 limbs in patients receiving no
anticoagulation or antiplatelet agents (control group [CG]). Forty percent of AG patients were also receiving antiplatelet
therapy. Periprocedural bleeding and closure rate at 1 year were evaluated.
Results: No major bleeding occurred in either group. Minor bleeding was noted in 8 of 88 procedures in the AG vs 4 of
92 in the CG (P 0.24); all in patients receiving radiofrequency ablation. Four of the eight minor bleeds in the AG were
noted in patients receiving “triple therapy” with warfarin, aspirin, and clopidogrel or ticlopidine. Triple therapy in the
AG was associated with a higher risk of minor bleeding compared with the CG (relative risk, 13.0; 95% confidence
interval, 4.10-41.19, P < .001). All treated venous segments remained closed at the 1-year follow-up in both groups.
Conclusions: In this relatively small, nonrandomized study comparing endovenous thermal ablation in patients with and
without warfarin, no differences were found in periprocedural risk of major bleeding or closure rate of the treated venous
segments. Minor bleeding was increased in patients receiving triple therapy with warfarin, aspirin, and a thienopyridine
who underwent radiofrequency ablation. (J Vasc Surg 2011;53:147-9.)Endovenous thermal ablation (ETA) has emerged as a
highly effective modality in the treatment of superficial
venous reflux disease.1-3 There are a growing number of
patients requiring this form of treatment who, for a variety
of reasons, have been prescribed warfarin for systemic anti-
coagulation. Concern has been raised about the potential
bleeding risk and whether anticoagulation needs be with-
held before ETA. This concern has further extended to
possible adverse effects of anticoagulation on the closure
rate of the treated venous segments at medium-term and
long-term follow-up. There are a paucity of data addressing
these concerns.4 The purpose of this study was to evaluate
the effects of uninterrupted anticoagulation in patients
undergoing ETA.
MATERIALS AND METHODS
From February 2008 through April 2009, 60 consecu-
tive patients (88 limbs) who were receiving anticoagulation
therapy with warfarin underwent ETA for significant symp-
tomatic venous reflux disease in the great saphenous vein
(GSV) at our office. ETA consisted of radiofrequency ab-
lation (RFA) with ClosureFast VNUS (Kendall/Covidien,
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These patients formed the anticoagulation group (AG).
Laser ablation was performed using an 810-nm diode laser
(PhotoMedex Inc, Montgomeryville, Pa). They were com-
pared with a control group (CG) of 65 consecutive patients
(92 limbs) during the same period who were not taking
warfarin or antiplatelet agents. ETA in the CG consisted of
RFA in 49 limbs and laser ablation in 43. ETA was the only
procedure performed, and there was no additional stab
phlebectomy or sclerotherapy in these patients.
The AG consisted of those patients in our practice who
were on anticoagulation with warfarin as the sole anticoag-
ulant and who underwent ETA during the study period
without other invasive venous procedures. The CG patients
were the first 65 consecutive patients who were not on
anticoagulation or antiplatelet therapy and who had con-
sented to be included in the study when the trial started. A
total of 348 ETA procedures were performed during the
study. No preference was given to any particular device, and
device use was according to the operator’s preference,
availability of the device at the time of the procedure, and
occasionally, a patient’s specific request for a particular
device. All procedures were done by one operator (M.S.).
Access to the GSV was obtained under ultrasound
guidance and using a micropuncture needle. The study end
points were major or minor bleeding 1 week of the
procedure and closure of the treated venous segment at 1
year. A hemogram was obtained in all patients 1 week
before the procedure and at 5 to 7 days thereafter.
Major bleeding was defined as a drop in hemoglobin of
2 g/dL or the need for transfusion.5 Minor bleeding was
defined as oozing from the access site after the procedure
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the necessity to change the bandages more than three times
within the first 24 hours. Patients and family members were
advised of the possibility of bleeding at home and in-
structed on how to apply pressure, record the time that
pressure was applied, and notify the physician should this
complication arise. For minor bleeding that developed in
the office, the physician or office staff applied manual
compression and accurately measured its duration. For
those at home, family members applied the manual com-
pression, and the duration of manual compression was
reported to the office.
After ETA, circumferential compressive bandages were
firmly applied from the metatarsal area, which extended to
the proximal thigh. The bandages consisted of a three-layer
wrap of 6-inch gauze, Coban, and ACE wraps (3M Co,
Maplewood, Minn). All patients were seen 2 days for
evaluation of the access site. A venous duplex scan was
performed for evaluation of efficacy of GSV closure imme-
diately after the procedure, at 1 week, and at 1, 6, and 12
months. The indication for anticoagulation is given in
Table I. Some patients had more than one indication for
anticoagulation.
Statistical analysis. Continuous variables were com-
pared using the two-sided t test. Categoric variables were
analyzed using the Fisher exact test. A value of P .05 was
considered statistically significant. All continuous values
were recorded asmean SD. Relative risk (RR) ratios, with
95% confidence intervals (CI), were used to express change
in risk across levels of the binary variables. All calculations
were performed using SPSS 18 software (SPSS Inc, Chi-
cago, Ill).
RESULTS
Patient baseline clinical characteristics are given in Ta-
ble II. Two patients in each group were lost to follow-up at
1 year. In the AG, 22 patients were taking aspirin (81-325
mg daily). Five of these patients were also taking clopi-
dogrel (75 mg daily), and two were taking ticlopidine (250
mg twice daily). Two patients were taking clopidogrel but
not aspirin. Therefore, “triple therapy” was noted in seven
patients both during the procedure and at 1 year (Fig).
No major bleeding occurred in any patients. Mean
hemoglobin (g/dL) before and after the procedure was
14.1  2.3 and 14.8  2.1 in the AG and 14.7  1.9 and




Atrial fibrillation 38 (63)
Prosthetic cardiac valve 4 (7)
Venous thromboembolic disease 17 (28)
Paradoxical embolization 6 (10)
Other 2 (3)
aAdded values100% because some patients had more than one indication.14.5  2.5 in the CG, respectively (P  .08 and .62).Minor bleeding was seen in eight limbs of the AG and in
four limbs of the CG (RR, 2.09; 95% CI, 0.65-6.70;
P  .24).
Of the eight minor bleeding episodes in the AG, four
occurred in patients on triple therapy who had received
RFA. For patients taking warfarin alone or warfarin plus
one antiplatelet agent, minor bleeding was noted in 3 of 64
and 1 of 17, respectively (P  .99) When patients taking
warfarin alone or warfarin plus a single antiplatelet agent
were compared with the CG, no excess rate of minor
bleeding was observed (P .99 for both comparisons). All
minor bleeding episodes in both groups occurred in pa-
tients who had received RFA. In the triple therapy patients
undergoing RFA, minor bleeding was significantly higher
than in the CG (RR, 13.0; 95% CI, 4.10-41.19; P .001)
and in those with anticoagulation plus one antiplatelet
agent (RR, 11.57; 95% CI, 3.66-36.58; P  .001). The
Table II. Clinical characteristics of anticoagulation (AG)







Mean  SD P
Patients 60 65
Limbs 88 92
Age, year 72  12.4 55  11 .001
Male 37 (62) 31 (48) .15
Cardiovascular disease 27 (45) 5 (8) .001
Diabetes mellitus 16 (28) 8 (5) .03
Hypertension 24 (40) 7 (11) .001
Hypercholesterolemia 13 (22) 10 (16) .49
GSV diameter, mm 4.2  1.3 3.7  2.2 .13
CEAP clinical class
1-2 5 (8) 14 (22) .034
3-4 49 (82) 47 (72) .001
5-6 6 (10) 4 (6) .426
GSV, Great saphenous vein.
Fig. Venn diagram demonstrates the distribution of antiplatelet
therapy in the anticoagulation group (AG). All patients were
taking warfarin: warfarin alone, 36 patients; additional aspirin
alone, 15 patients; aspirin thienopyridine, 22 patients; thienopy-
ridine without aspirin, 2 patients; total thienopyridine, 9 patients
(7 on clopidogrel, 2 on ticlopidine).mean international normalized ratio (INR) was 2.7  0.7
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taking one antiplatelet agent, and 2.4  0.4 for the 36
patients on anticoagulation alone. The INR of patients on
triple therapy was not significantly different than that of patients
on anticoagulation alone (95% CI, –0.35 to 0.95, P .31).
Three of eight of the minor bleeds in the AG, and two
of the four minor bleeds in the CG occurred in the office
and before discharge. The remainder occurred 6 hours
after discharge. All were controlled with leg elevation and
manual pressure for 13 2 minutes. One of the definitions
of minor bleeding was the necessity to change the bandages
more than three times within the first 24 hours. However,
none of the patients with minor bleeding was defined by
this criterion. In fact, changing bandages due to bleeding
was not required in any patient. After the procedure, com-
plete closure of the treated segments was verified by duplex
imaging in all. All treated venous segments had remained
closed at the 1-year follow-up in both groups.
DISCUSSION
The results of this prospective observational cohort
study indicate that ETA is not associated with any signifi-
cant periprocedural bleeding in patients taking warfarin.
ETA can be safely performed in patients on therapeutic oral
anticoagulation without the necessity for interruption of
anticoagulation. We have previously shown that anticoag-
ulation need not be withheld or reversed in patients under-
going percutaneous endovenous intervention for deep ve-
nous thrombosis, even when accessing the popliteal vein.5
Furthermore, intervention in the deep venous system is not
associated with increased bleeding complications in pa-
tients with supratherapeutic INR (as high as 6).6 In this
study, no major bleeding was noted with ETA irrespective
of the anticoagulation status of patients. Patients taking
warfarin and one antiplatelet agent had no increased risk of
minor bleeding compared with the CG. A higher rate of
minor bleeding was noted in patients taking triple therapy
who underwent RFA. This finding was not seen in similar
patients undergoing laser ablation. This differencemay have
been due to the lower profile of the 4F laser catheter com-
pared with the 7F RFA sheath. However, these results should
be interpreted with caution because the study was underpow-
ered, particularly in relation to differences noted in patients on
triple therapy receiving RFA and laser ablation.
Minor bleeding was easily controlled with additional
manual compression and leg elevation, without any serious
sequelae. It did not occur6 hours of office discharge. At the
1-year follow-up, the treated venous segments remained
closed in all patients. There was therefore no adverse effect of
anticoagulation or antiplatelet therapy on closure rate. A re-
cent small study comparing closure rates ofGSV in patients on
and off of warfarin undergoing laser ablation observed a trend
toward an adverse affect of warfarin on the closure rate,
although this difference did not reach statistical significance.4
Furthermore, no major bleeding complications occurred in
patients receiving anticoagulation therapy.4
In this study, patients in the AG were older with more
peripheral arterial and coronary artery disease and had ahigher use of concomitant antiplatelet agents. Yet despite
the potential fragility of the venous wall, a higher clinical
CEAP score, and concomitant antiplatelet use, no major
bleeding was noted. By study design, CG patients were not
receiving antiplatelet therapy to eliminate any effects of
platelet inhibition on the study end points.
Although patients receiving anticoagulation or anti-
platelet therapy are expected to have a higher bleeding rate
after the procedure, ultrasound-guided intervention in the
venous system, particularly in the superficial veins, is not
associated with any clinically significant bleeding.5,6 Pa-
tients who are receiving anticoagulation therapy usually
have serious cardiovascular and valvular heart disease, and
reducing or stopping their drugs would unnecessarily ex-
pose them to an undue risk of thromboembolism. Conse-
quently, when intervening in the venous system, especially
in the superficial veins, the benefits of reduction of antico-
agulation would not outweigh the risks.
CONCLUSIONS
In this relatively small, nonrandomized study compar-
ing endovenous thermal ablation in patients with and with-
out warfarin, no differences were found in the periproce-
dural risk of major bleeding or closure rate of the treated
venous segments. The minor bleeding rate was increased in
patients receiving triple therapy with warfarin, aspirin, and a
thienopyridine who underwent radiofrequency ablation.
AUTHOR CONTRIBUTIONS
Conception and design: MS, FE, JS
Analysis and interpretation: MS, MM, CB, FE, JS
Data collection: MS, MM, FE, CB
Writing the article: MS, MM, JS
Critical revision of the article: MS, FE, JS
Final approval of the article: MS, MM, CB, FE, JS
Statistical analysis: MS, CB, JS
Obtained funding: Not applicable
Overall responsibility: MS
REFERENCES
1. Proebstle TM, Vago B, Alm J, Göckeritz O, Lebard C, Pichot O.
Treatment of the incompetent great saphenous vein by endovenous
radiofrequency powered segmental thermal ablation: First clinical expe-
rience. J Vasc Surg 2008;47:151-6.
2. Roth S. Endovenous radiofrequency ablation of superficial and perfora-
tor veins. Surg Clin North Am 2007;87:1267-84.
3. Ravi R, Trayler EA, Barrett DA, Diethrich EB. Endovenous thermal
ablation of superficial venous insufficiency of the lower extremity: single-
center experience with 3000 limbs treated in a 7-year period. J Endovasc
Ther 2009;16:500-5.
4. Theivacumar N, Gough M. Influence of warfarin on the success of
endovenous laser ablation of the great saphenous vein. Eur J Vasc
Endovascular Surg 2009;38:506-10.
5. SharifiM,MehdipourM, Bay C, SmithG, Sharifi J. Endovenous Therapy
for Deep Venous Thrombosis : The TORPEDO Trial. Catheteriz Car-
diovasc Interv 2010;76:316-25.
6. Sharifi M, Mehdipour M. Percutaneous therapy of acute on chronic lower
extremity venous occlusive disease. Catheteriz Cardiovasc Interv 2010;75:
685-9.Submitted May 30, 2010; accepted Jul 27, 2010.
